期刊文献+

前列汤治疗慢性盆腔疼痛综合征湿热瘀阻证临床研究 被引量:2

Treatment of chronic pelvic pain syndrome (TCM syndrome of damp-heat and blood-stasis obstruction) with Qianlie Decoction
原文传递
导出
摘要 目的评价前列汤治疗慢性盆腔疼痛综合征(CPPS)湿热瘀阻证的有效性和安全性。方法142例患者随机均分为2组:中药组口服前列汤,每日1剂,分2次服;对照组口服塞来昔布胶囊200mg,每日1次。疗程均为4周。治疗前后检测前列腺按摩液(EPS)中白细胞(WBC)和卵磷脂小体(SPL)计数,进行慢性前列腺炎症状评分(CPSI)及中医证候评分,分析治疗前后的差异并进行两组间比较。结果治疗后中药组CPSI评分较治疗前下降了11分,中医证候积分下降了14.14分,WBC下降了5.86;对照组CPSI评分较治疗前下降了9.85分,中医证候积分下降了9.80分,WBC下降了7.76。两组各项指标治疗前后的差值均有显著统计学意义(P<0.01),两组间差异无统计学意义(P>0.05)。两组治疗后SPL计数分级均明显升高(P<0.01),中药组优于对照组(P<0.01)。两组治疗CPPS湿热瘀阻证的疗效差异无统计学意义(P>0.05)。结论前列汤治疗CPPS湿热瘀阻证有效、安全。 Objective To evaluate the efficacy and safety of Qianlie Decoction in treating chronic pelvic pain syndrome (CPPS, TCM syndrome of damp-heat and blood-stasis obstruction). Methods The patients (n = 142) were randomly divided into the treatment group treated with Qianlie Decoction ( 1 dose daily taken by 2 times), and the control group was treated with Celecoxib Capsules (200 mg once daily). The treatment course was for 4 weeks in two groups. The count of WBC and SPL in EPS were detected before and after the treatment. The scores of NIH-CPSI and TCM syndromes, and the difference between tow groups were compared and evaluated before and after the treatment. Results After the treatment In the treatment group the scores of NIH-CPSI was induced by 11, scores of TCM syndromes, by 14.14 and WBC, by 5.86. In the control group the scores of NIH-CPSI was induced by 9.85, scores of TCM syndromes, by 9. 80 and WBC, by 7. 76. The difference in all indexes in two groups was statistically significant before and after the treatment ( P 〈 0.01 ). The difference between 2 groups was not significant statistically ( P 〉 0.05 ). SPL counts were all increased significantly in two groups ( P 〈 0. 01 ), and the result of the treatment group was better than that of the control group (P 〈 0.01 ). The difference between two groups in the curative effect on CPPS (TCM syndrome of damp-heat and blood-stasis obstruction) was not statistically significant ( P 〉 0. 05 ). efficacious and safe for treating CPPS (TCM syndrome of damp-heat Qianlie Decoction is and blood-stasis obstruction).
出处 《北京中医药大学学报》 CAS CSCD 北大核心 2007年第12期850-853,共4页 Journal of Beijing University of Traditional Chinese Medicine
基金 中日友好医院科研资助项目(No20053082)
关键词 慢性盆腔疼痛综合征 前列汤 湿热瘀阻 临床研究 chronic pelvic pain syndrome Qianlie Decoction syndrome of damp-heat and blood-stasis obstruction clinical experiment
  • 相关文献

参考文献7

  • 1LITWIN MS, MCNAUGHTON COLLINS M, FOWLER FJ JR, et al. The National Institutes of Health chronic prostatiffs symptom index: development and validation of a new outcome measure [ J ]. J Urol, 1999,162 (2) :369 - 375.
  • 2SCHAEFFER AJ,DATTA NS,FOWLER JE, et al. Overview summary statement[ J ]. Urology, 2002,60( 6 Suppl) :1 -4.
  • 3NICKEL JC. The pro and post massage test(PPMT):a simple screen for prostatitis[ J]. Tech Urol,1997,3(1) :38 -43.
  • 4NADLER RB,KOCH AE,CALHOUN EA, et al. IL- 1 beta and TNF -alpha in prostatic secretions are indicators in the evaluation of men with chronic prostatitis [ J]. J Urol,2000,164(1) :214- 218.
  • 5段志国,杨为民.细胞因子与慢性前列腺炎关系的研究现状[J].中国男科学杂志,2005,19(1):57-59. 被引量:12
  • 6曾晓勇,叶章群,杨为民,刘继红,张旭,周惜才,周四维.塞来昔布治疗ⅢA型前列腺炎的临床评估[J].中华男科学杂志,2004,10(4):278-281. 被引量:25
  • 7李兰群,王传航,刘春英,李海松,孙自学,陈武山,鲍身涛,李曰庆,胡立胜.慢性前列腺炎中医证型分布频率研究[J].中华中医药杂志,2005,20(4):245-246. 被引量:120

二级参考文献35

  • 1James M J, Penglis PS, Caughey GE, et al. Eicosanoid production by human monocytes: does COX-2 contribute to a self-limiting inflammatory response [ J ]? Inflamm Res, 2001,50 (5) :249-253
  • 2Schaeffer AJ, Datta NS, Fowler JE Jr, et al. Overview summary statement. Diagnosis and management of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) [J]. Urology, 2002, 60(6Suppl) :1-4.
  • 3Gurunadha Rao Tunuguntla HS, Evans CP. Management of prostatitis[ J ]. Prostate Cancer Prostatic Dis, 2002, 5 (3) : 172-179.
  • 4Simon LS. COX-2 inhibitom. Are they nonsteroidal anti-inflammatory drugs with a better safety profile [ J ] ? Gastmenterol Clin North Am, 2001, 30(4) :1011-1025.
  • 5Goldenberg MM. Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis[J].Clin Ther, 1999, 21(9) :1497-1513.
  • 6Nickel JC, Pontari M, Moon T, et al. A randomized, placebo controlled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis[J]. J Urol, 2003, 169(4) :1401-1405.
  • 7Tanaka A, Hase S, Miyazawa T, et al. Up-regulation of cyclooxygenase-2 by inhibition of cyclooxygenase-1: a key to nonsteroidal anti-inflammatory drug-induced intestinal damage[J]. J Pharmacol Exp Ther, 2002, 300(3):754-761.
  • 8Schaeffer AJ, Landis JR, Knauss JS, et al. J Urol 2002;168:593-598.
  • 9Schaeffer AJ, Knauss JS, Landis JR, et al. J Urol 2002;168:1048-1053.
  • 10Nickel JC, Nyberg LM, Hennenfent M, et al. Urology 1999; 54:229-233.

共引文献148

同被引文献27

引证文献2

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部